AU653362B2 - Insertion of DNA by modified transposons - Google Patents

Description

$533 62

AUSTRALIA

PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT

ORIGINAL

S F Ref: 191448 0

S.

*4 'h *0

S

00..

Name and Address of Applicant: Actual Inventor(s): Address for Service: Invention Title: American Cyanamid Company One Cyanamid Plaza Wayne New Jersey 07470 UNITED STATES OF AMERICA Robert Newton Brey III, Robert Allen Deich Spruson Ferguson, Patent Attorneys Level 33 St Martins Tower, 31 Market Street Sydney, New South Wales, 2000, Australia Insertion of DNA by Modified Transposons 0 S 0 S. S

S

The following statement is a full description of this invention, including the best method of performing it known to me/us:-

S

4rOO *5 .5 0* 5845/3 31638 INSERTION OF DNA BY MODIFIED TRANSPOSONS BACKGROUND OF THE INVENTION Prokaryotic transposable elements are discrete DNA sequences capable of insertion at single or multiple sites within a prokaryotic genome (for a review see D.E. Berg ed., (1989) Mobile DNA, ASM Publications, Washington, Historically, these transposable elements have been divided into 3 classes.

0 *5 The first class comprises small transposable elements, generally less than 2,000 base pairs in length. These elements are called insertion sequences or IS sequences, and encode only determinants relevant to their own transposition; specifically, a transposase protein. This first class also includes composite transposons which are a segment of DNA flanked by two copies of an insertion sequence. The terminal portions 0 of all IS sequences comprise inverted repeat sequences.

The transposase protein functions by recognizing these terminal sequences and interacting with the sequences to effect transposition within the genome.

The second class of transposons is the Tn3 family of transposons. These transposons encode two 4S° products involved in a two-step transposition process; 1 a transposase and a resolvase. Transposons belonging to this second class have inverted terminal repeats of approximately 35-40 base pairs.

The third class includes bacteriophage Mu and related phages. Bacteriophage Mu is large relative to other transposons with a genome of 36,000 base pairs.

Mu encodes two gene products which are involved in the transposition process, a 70,000 dalton transposase and an accessory protein of approximately 33,000 daltons.

An unusual feature of Mu that distinguishes it from other transposons is that its ends are not inverted repeat sequences. The Mu transposase has, however, been shown to bind to both ends in an in vitro binding assay.

The use of transposons as vehicles for the introduction of foreign DNA into a host cell chromosome has been described previously Way et al., Gene 32:369-379 (1984)). Also, Grinter (U Patent No.

4,784,956) describes a two-vector method for inserting 2 a transposable cloning vector into the chromosome of a recipient cell. The first plasMid carries a transposon having the gene encoding its transposase function replaced with foreign DNA to be inserted into the lb" chromosome of the recipient cell. The second plasmid carries an expressible transposase gene. The transposase function is, therefore, provided in trans.

Narang et al. Patent No. 4,830,965) describe a construct referred to as a transposable linker. The linker comprises the extreme ends, or

*VA*

30 transposase recognition sequences of a transposon. The genetic material which is flanked by the transposase recognition sequences in the naturally occurring transposon has been replaced with a DNA sequence ,V containing restriction enzyme recognition sequences to ".35 facilitate the insertion of a foreign DNA sequence. As was the case with the Grinter method, Narang et al.

2 a. a 00..

.0.0 .00.

e: go..

0 *4 3 teaches the introduction of a gene encoding a transposase protein on a separate plasmid vector, in trans.

Summary of the Invention This invention pertains to a DNA construct for the introduction of a DNA sequence into the constituent DNA of a prokaryotic cell. The DNA construct comprises a gene encoding a transposase protein linked, in cis, to a transposable cassette. The transposable cassette comprises a pair of transposase recognition sites (usually inverted repeats) flanking a cloning site for the insertion of the DNA sequence to be introduced into the constituent DNA of the prokaryotic cell.

According to a first embodiment of this invention, there is provided a DNA construct for introducing a DNA sequence into the constituent DNA of a prokaryotic cell, the construct comprising a gene encoding a transposase protein linked in cis to a transposable cassette, the cassette comprising a pair of transposase recognition sites flanking both a selectable marker gene and a cloning site for insertion of the DNA sequence, but the cassette not having transposition recognition sites that flank both the selectable marker gene and the gene encoding the transposase protein, such that the selectable marker gene and the gene encoding the transposase protein do not both transpose in a single transposition event.

According to a second embodiment of this invention, there is provided an episome 20 for introducing DNA into the constituent DNA of a prokaryotic cell, the episome comprising: a) a gene encoding a transposase protein; b) a transposable cassette linked in cis to the gene encoding the transposase protein, the transposable cassette comprising a pair of inverted repeats flanking a multiple cloning site and a selectable marker, but not flanking the gene encoding the transposase protein; and c) a replicon having an origin of replication which is substantially homologous and functionally equivalent to a prokaryotic origin of replication.

According to a third embodiment of this invention, there is provided a bacteriophage derivative for introducing DNA into the constituent DNA of a prokaryotic cell, the bacteriophage derivative comprising: a) a gene encoding a transposase protein; b) a transposable cassette linked in cis to the gene encoding the transposase protein, the transposable cassette comprising a pair of inverted repeats flanking a multiple cloning site and a selectable marker, but not flanking the gene encoding the transposase protein; and c) an origin of replication which is substantially homologous and functionally equivalent to a bacteriophage origin of replication.

L[GWPUSER\LIBVVI00303:TCW 3A According to a fourth embodiment of this invention, there is provided a live vaccine comprising an attenuated bacterium having incorporated in its constituent DNA a transposable cassette, the cassette comprising a pair of transposase recognition sites flanking both a selectable marker gene and an expressible gene encoding an antigen of interest, but the cassette not having transposition recognition sites that flank both the selectable marker gene and the gene encoding the transposase protein, such that the selectable marker gene and the gene encoding the transposase protein do not both transpose in a single transposition event.

According to a fifth embodiment of this invention, there is provided a method for o1 introducing a DNA sequence into the constituent DNA of a prokaryotic cell comprising the steps of:

S

9S*

S

S

S

*SS

a) introducing a DNA construct into the prokaryotic cell under conditions appropriate for transposition, the DNA construct comprising a gene encoding a transposase protein linked in cis to a transposable cassette, the cassette having a pair of transposase recognition sites flanking both a selectable marker gene and a cloning site for insertion ox DNA sequence, but the cassette not having transposition recognition sites that flank both the selectable marker gene and the gene encoding the transposase protein, such that the selectable marker gene and the gene encoding the transposase protein do not both transpose in a single transposition event; and b) identifying recipient cells having the DNA sequence inserted into the constituent DNA.

According to a sixth embodiment of this invention, there is provided a method for introducing a DNA sequence into the constituent DNA of a prokaryotic cell at a 25 predetermined genetic locus, the prokaryotic cell containing a resident transposon at the predetermined genetic locus, the method comprising: a) introducing a DNA construct into the prokaryotic cell, the DNA construct comprising: i) a transposable genetic cassette having a pair of transposase recognition sites flanking a selectable marker and the DNA sequence; ii) a gene encoding a transposase protein linked in cis to the transposase cassette, the encoded protein recognizing both the vector born transposase recognition sites, and the transposase recognition sites of the resident transposon; and b) identifying prokaryotic cells having the DNA sequence inserted into the constituent DNA of the prokaryotic cell at the predetermined genetic locus.

The invention can be used, for exar iple, to insert single or multiple copies of an expressible gene into the chromosome of a prokaryotic host. This enables the efficient production of antigenic material for vaccine applications. Furthermore, if the prokaryotic

'M

GA\WPUSERnLIBVVI00303TCW 3B host is an attenuated enteroinvasive bacterium, the invention is useful for the construction of a strain useful in a live vaccine formulation.

Providing the transposase function in cis linked on a continuous DNA molecule) offers many advantages over known techniques in which the function is provided in trans. For example, if the DNA sequence to be introduced is carried on a separate vector from the gene encoding the transposase protein, then co-transformation of a cell with both vectors is necessary to achieve the desired result. The construct of this invention enables the introduction of a transposable sequence by transforming a cell with a single vector. This is a more efficient and convenient methodology because it reduces the number of cells which must be screened in order to identify a clone having the desired properties.

o* e [G:\WPUSER\LIVV100303;TCW Another advantage relates specifically to the IS transposons. The IS transposases have been shown to be inefficient when introduced in trans. Complementation in trans of an IS transposon with a defective transposase occurs with an efficiency of about 1% or less (see Morisato et al., Cell 32:799-807 (1983)). One explanation which has been advanced for this phenomenon is that the IS encoded transposases bind nonspecifically to DNA sequences which are physically close to the transposase gene immediately upon synthesis. These nonspecifically bound molecules then scan the DNA in search of transposase recognition sequences by one-dimensional diffusion along the DNA (Berg et al., (1981) Biochemistry 20:6929-6948). In contrast, the DNA constructs of the present invention encode the transposase gene and the transposase recog- 066* ooo nition sequences in cis, resulting in an efficient transposition system.

20 Brief Description of the Drawings Figure 1 is a diagram representing a DNA construct of this invention.

Figure 2 is a diagram representing steps in the construction of a DNA construct of this invention.

Figure 3 is a diagram representing the DNA sequence of a synthetic oligonucleotide specifying the left end of the prokaryotic transposon TnlO and (B) the DNA sequence of a synthetic cloning linker for use with synthetic transposase recognition sequences.

Figure 4 is a diagram representing two DNA constructs of this invention which are derived from bacteriophage A.

Figure 5 is a diagram representing a transposon exchange reaction between a plasmid and a bacteriophage.

4 Figure 6 is a diagram representing steps in the construction of a bacteriophage based DNA construct of this invention which carries an expressible Plasmodium berqhei circumsporozoite gene.

Figure 7 is a diagram representing steps in the construction of a plasmid based genetic construct of this invention which carries an expressible LT-B gene.

Figure 8 is a diagram representing schematically chromosomal transposon insertion in Salmonella.

Figure 9 is a diagram representing a synthetic oligonucleotide linker specifying restriction sites unique in bacteriophage A.

Figure 10 is a diagram representing the results of electroporation of pPX1575 into H. influenzae 0 Detailed Description of the Invention The subject invention relates to DNA con- 0 structs for the introduction of a DNA sequence into the constituent DNA of a prokaryotic cell, and to methods for their use. The constituent DNA of the prokaryotic cell includes all autonomously replicating DNA molecules within the cell including, for example, chromo- 4..,.0j5 somes and episomes. Transposition is often independent of the constituent DNA sequence of the prokaryotic cell Sand therefore transposition generally occuts at random locations. However, transposons can also, with a high frequency, exchange with other transposons of the same type via transposition or double recombination between tranposase recognition sequences. As discussed below, this exchange mechanism facilitates the insertion of a transposon carrying, for example, a gene of interest at a specific location in the constituent DNA of a host cell.

5 This invention can be used to introduce a DNA sequence having or encoding any function. For example, the DNA sequence can comprise a sequence ence. ing a structural or regulatory protein, or can comprise a regulatory sequence such as a promoter. Alternatively, the inserted sequence can be one not known to possess any biological function which can be used to interrupt a cellular function, for example, by inserting itself within an essential gene thereby interrupting the function of the gene.

In preferred embodiments, the DNA sequence to be introduced into the constituent DNA of a prokaryotic cell is an expressible gene. The expressible gene includes all necessary regulatory sequences including, for example, a prokaryotic promoter, ribosome binding site, etc.

The invention describes basic methodology to insert single or multiple copies of genes into chromosomes of diverse species. Expressible genes can be 20 derived from eukaryotic sources and can encode antigenic components from pathogenic parasites, human immunoactive proteins and peptides, hormones, growth factors, allergens, tumor associated antigens and other proteins. Such genes can be derived from viral sources 25 and can encode antigenic proteins, structural components, or enzymes involved with viral replication or attachment. Homologous genes as well as heterologous genes can be derived from bacterial, viral, parasite, fungal or mammalian sources and may include genes encoding virulence factors of pathogenic organisms, including toxins, protective immunogenic proteins, or genes encoding proteins involved in the regulation or synthesis of antigenic polysaccharide material, and in addition can be enzymes foreign to the host bacterium.

Among the bacterial antigens of interest are those associated with the human bacterial pathogens 6

S

S. Se .5 S S S a 55

S

S.

*555

S

o 5s 9 5S including, for example, typable and untypable 11aemphilus influenzae, Escherichia coli. Neisseria nenincaitidis, Strentococcus P-neumoniae, Streptococcus pyocege&s, Br i~lJ~ catarrhalis, Vibrio ch~l re, Corynebacterium Uphtheriae, ChlamvdiA trachomatis, Neisseria ctonorrhose, Bordetallna Rertussis, Pseudomonas, aerucrinosa, St~phylococcus aureus, Streptococcus pyocrenes, Kiebsiella pneumoniae, and Clogtridium tetani. Examples of specific bacterial antigens of interest include bacterial proteins of which particularly useful examples are outer membrane proteins (e.g.

from Mjlemophilus influenzae, Branhamella pektarrhalis or Neissetia menincritidis) bacterial toxins, pertussis toxins, diphtheria toxin, tetanus toxin, and Pseudomonas exotoxin and bacterial surface proteins flagellins, hemagglutinins and the M protein from Atrppto;,lqscs pyocrenes-).

viral antlqans from pathogenic viruses include but are not limited to, human immunodeficiency virus (types I and II)o human T lymphocyte virus (types 1, XX and III) respiratory syncytial vivuso hepatitis A, hepatitis B, hepatitis c, non-A and non-B hepatitis viruses, herpes simplex virus (tyipes I and XII cytomegalovrirus, influenza virus, parainfluenz4 virus, poliovirus, rotavirus, coronavixus, ,ella virus, measles virus, varicella, Epstein Barr virus, adenovirus, papilloma virus and yellow fever virus.

Several specific viral antigens of these pathogenic viruses include the P (peptide 283-315) and G proteins of respiratory syncytial virus (flSV), VP4 polypeptide of rotavirus, VP7 polypeptide of rotavirus, envelope glycoproteins of human immunodeficiency virus and the S and pre-$ antigens of hepatitis B.

Genes encoding antigents of parasites and fungi can also be used in the present invention.

Parasite antigens of interest include,. for example,

S

25 *555 S S 55 p W5S* S S *5 9

S..

S

0S -7 those of Plasmodium spp., Toxoplasma spp., Leishmania spp., Trypanosoma spp., Schistosoma spp., Toxocara spp., Ascaris spp., and Pasciola spp. Fungal antigens include those of Candid albicans, Cryptococcus neoformans and Coccidiodes immitis.

Also of interest are various antigens associated with auto-immune diseases, such as rheumatoid arthritis and lupus erythematosus, tumor antigens, cancer antigens and single or multiple copies of genes encoding hormones, bioactive peptides, cytokines, lymphokines and growth factors, as well as enzymes and structural proteins of prokaryotic or eukaryotic *-rigin, especially for use in vaccines and therapeutics.

13 To provide novel vaccine formulations, genes encoding protective antigens can be introduced into the chromosomes of attenuated bacteria, which act as delivery vehicles for stimulation of immune responses against the pathogen from which the expressed gene was 20 derived. See Dougan and Tite, Seminars in virology 1:29 (1990). Genes encoding antigens derived from pathogenic bacterial, viral, or parasitic sources can be introduced into chromosomes of attenuated S. typhi for use as live vaccines for use in humans (to protect 0* :25 against, for example, typhoid fever, diarrheal diseases, and setually transmitted diseases including AIDS). Alternatively, such genes can be integrated into chromosomes of other Salmonella capable of infecting animal species, S. dublin for use as live attenuated cattle vaccines against shipping fever), S. choleraesuis for use as live attenuated vaccines for swine, and S. gallinarum or S. pullorum for use as live attenuated vaccines for poultry. In a particular embodiment, antigens derived from Eimeria parasites can be inserted into the chromosome of attenuated allinarum to produce an oral vaccine for 8 cocridial disease. Alternatively, genes encoding antigens can be inserted into chromosomes of other bacteria to be used as live vaccines. Examples of such can include attenuated i.nteroinvasive Escherichis coli, Yersinia enterocolitica, Shigella flexneri, S. dysentariae, Campylobacterium jejuni, Vibrio cholera, and Bacille Calmette-Guerin (BCG), an avirulent mutant of Mycobacterium bovis.

In addition, such genes can be inserted as single or multiple copies into bacterial chromosomes to provide for efficient production of antigenic material for vaccine production. Insertion of native or mutated genes derived from bacterial pathogens into chromosomes can result in enhanced and efficient antigen production. For example, genes encoding mutant toxins, genes encoding virulence factors, or other native or mutant *6 protective immunogens can be introduced into the chromosome of a homologous or heterologous bacterial strain. In many cases, virulence factors or protective 20 immunogens can be produced efficiently only in a particular host bacterium. In addition, genes which encode products involved in complex biosynthetic pathways leading to bacterial surface polysaccharide or capsule production are too large to be cloned and *25 expressed in other bacteria for the purpose of producing antigenic material for vaccine uses.

Examples of such uses include the insertion of cross-reacting mutated toxin molecules of Bordetella pertussis into the chromosome of toxin-deficient S 30 organisms for the production of an efficient pertussis vaccine and the insertion of altered regulatory signals enhancing the production of a mutant toxin gene product.

Antigenic capsular material derived from aemophilus influenzae type b can be obtained from fermentation of the bacteria. Insertion of altered 9 genes affecting regulation of capsule synthesis can lead to enhanced production of capsular material in H.

influenzae. Efficient production of immunogenic outer membrane proteins of H. influenzae can be enhanced by insertion of genes encoding aovel fusion proteins in a genetic background devoid of wild type outer membrane protein activity.

Expressible genes can be inserted into chromosomes resulting in recombinant organisms capable of high level production of protein products from a single gene copy. By random insertion of genes into chromosomal loci, bacteria expressing high levels of gene products can be isolated. Random localization leads to i-lates in which positional effects enhancing s1 gene expression can be detected. Enhanced gene expression can yield stable recombinants which express protein at levels exceeding similar gene constructs S. carried on multiple copy plasmid vehicles.

Expressible genes can be inserted into the 20 chromosome so that inheritanc of the inserted genes *e can be maintained indefinitely in a stable fashion.

1xtrachromosomal plasmid vectors which are commonly used for expression of foreign proteins can be unstable leading to loss of foreign gene expression. Insertion of genes into random or specific locations within bacterial chromosomes leads to stable inheritance and retention of gene expression.

It is possible to enrich for and to screen for stable insertion of multiple copies of the same gene in the chromosome of a bacterial strain. This invention provides for introduction of multiple copies of the same gene in the chromosome of the host organsism or one to several copies of different genes.

The DNA construct of this invention comprises a gene encoding a transposase protein linked in cis to a transposable genetic cassette as a single continuous 10 DNA molecule. The cassette comprises a pair of transposase recognition sites (usually inverted repeats) flanking a cloning site for insertion of the DNA sequence to be introduced into the constituent DNA of the prokaryotic cell, but not flanking the gene encoding the transposase protein.

Naturally occurring transposable elements have transposase recognition sites occurring at %heir and 3' termini. These ends and any internal DNA sequence can transpose throughout the constituent DNA of a cell. This internal sequence can vary greatly in length from approximately 1,500 base pairs in the case of IS sequences to much longer sequences in the case of phage Mu. A common feature of this internal sequence in all transposons is that a portion of it encodes a transposase which specifically recognizes the 5' and 3' terminal sequences, or transposase recognition sequences, of the particular transposon in which it is contained.

20 In contrast to the naturally occurring situation described above, the construct of this invention carries a transposable cassette having transposase recognition sequences, but these recognition sequences do not flank the transposase gene. The 25 transposase gene has been inserted at another location in the construct of this invention. The transposed sequence does not include ii transposase gene and is, thus, stably integrated in the absence of any external transposase gene. The methods of this invention enable one to stabilize a particular cloned prokaryoti. cell having a transposable cassette contained within its constituent DNA at a particular location.

Any set of transposase recognition sequences, and genes encoding the corresponding transposase can be used to practice this invention. In a preferred embodiment, the transposase recognition sequences 11 comprise inverted repeats. Naturally occurring transposons having inverted repeats include, for example, IS1, IS2, ISZ, IS4 and IS5; and the Tn elements including, for example, Tnl, Tn2, Tn3, Tn5, Tn9, TnlO and Tn903. The transposase recognition sequences of bacterophage Mu and related transposons, are also useful for the practice of this invention. The transposase recognition sequences of phage Mu and related transposons are not inverted repeats. Such sequences, and sequences encoding the corresponding transposase protein, can be isolated from the naturally occurring transposon using standard techniques.

Alternatively, such sequences, or sequences which are functionally equivalent and substantially homologous, can be synthesized chemically.

The construct of this invention is synthesized through a series of genetic manipulations employing methods and enzymes known to those skilled in the art. The two essential elements are the transpos- 20 able cassette and the expressible transposase gene.

4.

00,* These elements are linked in cis to form a single continuous DNA molecule. Preferably, as shown in Figure 1, this single continuous molecule is linked to an origin of replication which enables the conditional 25 propagation of the construct in at least one type of prokaryotic cell, and a selectable marker such as a gene encoding a protein conferring antibiotic resistance, the selectable marker being flanked by the trunsposase recognition sequence.

Although selectable markers which lead to antibiotic-resistance can be readily used to construct the above described modified transposable elements, drug-resistant organisms are not suitable for all purposes, especially for use in live bacterial vaccine applications, where dissemination of the drugresistance allele to other gut flora is possible.

12 During fermentation for production of recombinant proteins, enzymes and other products, addition of antibiotics to growth medium allows for selection for cells containing plasmids or modified transposable elements, but can be unacceptable in many instances because of cost and possible contamination of the endproduct. For the modified transposons described here, antibiotic-resistance is used to select for insertion, and can be eliminated during subsequent steps because of the inherent stability of the alements.

To replace the antibiotic-resistance determinants with selectable markers which could be used where dissemination of the organisms in the environment is possible, there are numerous strategies which can be applied. The modified transposons can be selected and •introduced into recipient cells by complementation of host chromosomal mutations. Complementation systems rely on construction of particular host chromosomal *.20 mutations, but can be used reliably to circumvent the 0** inclusion of antibiotics to the culture medium. Selectable markers that have been used in some instances to select and maintain plasmids in bacterial cultures during fermentation can be used to select transposition events. For example, complementation of a chromosomal mutation for aspartic semialdehyde dehydrogenase (asd) in Salmonella typhimurium or D-alanine racemase mutation (dal) in Bacillus subtilis, which each lead to l faulty cell wall biosynthesis and cell lysis, yields stable plasmid inheritance in the absence of selection in all viable cells of the culture. Both the asd and dal mutations can be supplemented with nutritional additives. Thus, transposons marked with a functional dal or asd gene can be selected in bacterial hosts containing those mutations. On the other hand, complementation of an essential gene of the host, which 13 cannot be provided by nutritional supplementation can also lead to stable plasmid maintenance. An E. coli gene, ssb, is required for DNA replication and cell viability, which prevents the accumulation of plasmidless cells during fermentation in a bioreactor when placed on a plasmid. Analogously, a plasmid-borne copy of valyl tRNA synthetase stabilizes plasmids in E. coli containing a chromosomal temperature-sensitive valyl tRNA synthetase. Plasmids can also be stabilized by inclusion of a bacteriophage repressor gene, the loss of which leads to induction of host prophage and cell death. So, functionally any of those selection systems can be applied to transposable elements described above. In addition, transposable elements can be modified to contain selectable markers which can be used in bacterial cell recipients which do not have to be modified by mutation to accept the marker. For instance, genes for resistance to heavy metals (Silver, S. and Misra, Ann. Rev. Microbiol., 1988, 42:717- :*20 743. Plasmid mediated heavy metal resistance) which are not used for human therapy can be introduced into the transposable elements. These markers would include genes which encode resistance to arsenite or arsenate, antimony, cadmium or organo-mercurial compounds. In a particular embodiment, the arsA and arsB genes, which are solely involved with resistance to arsenite, can be i* a easily adapted to the modified transposable elements.

oo ~Also useful as selectable markers are genes encoding resistance to herbicides. A number of such genes have been described, each conferring resistance to a limited range of herbicides, such as imidazolinones, sulfonylureas (Yadav et al., PNAS USA 83:4418-22, 1986) glyphosate (Comai et al., J. Biol. Chem,.

260:4724-4728, 1985); and phosphothrinicin and bialophos (Thompson et al., EMBO ft:2519-2523, 1987; DasSarma et al., science 232:1242-1244, 1986).

14 For particular application to attenuated Salmonella live vaccine applications, modified transposons can be marked with a gene which complements a secondary attenuating locus to insure vaccination of the host mammal with antigen-expressing organisms. For example, the gene for adenyl succinate synthetase, encoded by the purA gene, can be introduced into the modified transposons also containing an expressed antigen. Transposition events can be selected in Salmonella vaccine strains by selecting for adenine independence in a purA genetic background. When a purA mutation is present in conjunction with other attenuating mutations, such a" &roA, Salmonella cells are essentially hyper-attenuated and do not replicate in the mammalian host. Thus, vaccine strains which contain a purA-complementing transposon are fully immunogenic.

*p S* One skilled in the art can synthesize a genetic construct as described herein using well known **70 molecular cloning techniques. Furthermore, sources for each of the necessary starting components are generally available. For example, a gene encoding a selectable

R

marker such as Kan can be excised froml any of a number of common sources Tn5) by digestion with appropriate restriction enzymes. Sources for transposase recognition sequences and the corresponding transposon gene have been described above.

Figure 3A represents a synthetic oligonucleotide specifying the extreme 31 base pairs of the right end of TnlO; approximately 27 base pairs of Tn 10 is V* sufficient for recognition by the Tn 10 transposase (Way and Kleckner, Proc. Natl. Acad. Sci. USA 81:3452- 3456 (1984)). Cloning sites for insertion of the DNA sequence (preferably a multiple cloning site containing several unique restriction enzyme recognition sequences) are also widely available or can be synthe- 15 sized chemically. Figure 3B, for example, represents a synthetic cloning linker which was inserted into pPX1569 to generate pPX1572, as shown in Figure 2. The order and arrangement of the components is clearly provided in Figures 1 and 2. One skilled in the art will recognize that the positions of the transposase in the DNA construct is not critical provided that it is expressible, and outside of not flanked by) the transposase recognition sequences (generally inverted repeats). Similarly, the order of the selectable marker and the inserted DNA sequence can be the reverse of that shown in Figure 1, provided that both are flanked by the transposase recognition sequences. In a preferred embodiment, each of the above-identified components are positioned in a replicon containing vector DNA molecule. Any cloning vector, modified as *e described above, is appropriate.

a. *4 The construct described above can be propa- 4 gated by transforming a prokaryotic cell in which the 20 replicon is functional. The replicated construct can then used in further steps of genetic manipulation.

w' For example, using well known techniques any sequence a gene of interest), can be inserted into the cloning site of the transposable cassette and the new construct can be used to transform prokaryotic cells.

In the transformed cell the transposase gene will be transcribed, as it carries all of the necessary regulatory sequences promoter, ribosome binding Ssite, etc.). The transposase protein recognizes the ends of the transposable cassette thereby inducing its transposition into the constituent DNA of the cell.

The gene carried within the genetic cassette, which also has the necessary regulatory signals, will also be expressed.

In preferred embodiments, the replicon is conditional. A conditional replicon replicates under 16 permissive conditions, but not under restrictive conditions. The use of conditional replicons enables the stabilization of a particular cloned prokaryotic cell having a transposable cassette contained within its constituent DNA at a particular location. This stabilization is accomplished by removing or effectively inactivating the transposase gene (by growing the cell under restrictive conditions), and ultimately, the transposase protein, from the cloned cell.

For example, some plasmids carry a conditional defect, such as a temperature-sensitive replicon. Constructs of this invention which are derived from such plasmids have the ability to replicate at a permissive temperature, but cannot replicate at a restrictive temperature. Cells carrying the a.n* plasmid can, however, grow and divide at both temperatures. After a cell having a transposable cassette contained within its constituent DNA at a particular location is identified, the incubation temperature is shifted to the restrictive temperature. The cells continue to grow and divide but the construct does not replicate. The gene construct carrying the transposase gene, and consequently the transposase protein, is .25 thereby diluted to the ertent that the integrated S* transposable cassette is stabilized within the constit- 's uent DNA. An example of such a curable plasmid is the temperature sensitive E. coli F factor. Any replicon having such a conditional defect is useful in the practice of this invention.

Limited host-range plasmids are conditional and can also be used to enable the stabilization of a *4 desired integrate. Well known examples of this group of plasmids are derivatives of the E. coik colEl plasmid vector pBR322. These plasmids are small and easy to prepare in large quantities for in vitro 17 cloning steps. They are limited in host-range to E.

coli and closely related enterobacteria, and are replication incompetent in other species unless the E.

coli DNA polymerase I function is provided. This dependence is due to the requirement of the colEl origin of replication for the E. coli-like DNA polymerase I function. Hence, these plasmids can be used as suicide delivery vectors for other bacteria. Suicide delivery, as used herein, refers to the introduction of a transposon via a genetic construct which cannot replicate in the host. The plasmids direct the synthesis of the transposase protein upon transformation which results in the integration of the transposable cassette into the constituent DNA. However, because the replicon is replication incompetent in the prokaryotic cell selected, the tranposase protein is quickly diluted to the point where transposition no longer takes place.

Any plasmid vector which has limited host range can be a delivery vehicle for the modified transposons described above. For instance, the origin '4 of pBR327, used in construction of pPX1575 and its derivatives, freely replicates in E. coli and Salmonella, but fails to replicate in H. influenzae or B.

pertussis. Thus, pPX1575 is a suicide plasmid for 4* delivery of modified transposons to those bacterial cells. Conditional replicons for delivery of modified transposon to enteric bacterial hosts can be constructed as an alternative to delivery in bacteriophage such as lambda or temperature-sensitive F factors as described above. The origin of plasmid R6K requires a i functional r protein, which functions in trans for replication. Suicide vectors containing the R6K replicon have been constructed Miller, V.L. and Mekalanos, J.J. 1988, J. Bacteriol. 170:2575-2583).

Using E. coli hosts which contain the r protein in 18 trans, suicide plasmids carrying the modified transposable elements can be isolated. These suicide plasmids would act to deliver transposable elements, by transformation or by conjugation, to such bacteria as Salmonella, Shigella, and other closely-related enteric bacteria. Further, replicons derived from grampositive organisms, such as pUBl1O, originally isolated in S. aureus, fail to replicate in gram-negative bacteria such as E. coli or Salmonella, and thus can be used in construction of suicide plasmid vehicles for modified transposons.

A third type of DNA construct for delivery of the transposable cassette in a prokaryotic chromosome is a bacteriophage derivative. In a preferred embodiment, the bacteriophage is bacteriophage A. As shown in Figures 5 and 6, a phage which is unable to replicate in the prokaryotic host cell a conditional replicon) is used to deliver the transposable cassette.

The system takes advantage of the property of resident **20 transposons to spontaneously exchange in vivo. Hence, •ge if construction of a desired specialized transposon it carried out on a plasmid carrying a first selectable marker is introduced into an E. coli cell lysogenized with a A phage containing the suitable transposase recognition sequence flanking a second selectable marker, the plasmid transposon can exchange with the prophage transposon at a high frequency. such exchanges can easily be detected and isolated by inducing the resident prophage and screening the lysate for phage capable of transducing the first marker. These lysogens can then be induced to yield a pure population of transducing phage carrying the transposable genetic cassette. Another method for stabilizing a particular chromosomal insertion involves the use of a regulatable promoter to control expression of the transposase protein. Many regulatable promoters are known to those 19 skilled in the art including tac, lac, recA, PL, and T7. Such promoters are active under defined conditions, but inactive under other conditions.

The preceding discussion relates primarily to random insertion of a DNA sequence. However, by using a host cell containing a resident transposon at a predetermined genetic locus, it is possible to direct the insertion of a DNA sequence to that predetermined locus. This is due to specific transposition or homologous recombination between transposase recognition sequences (generally inverted repeats).

To determine the position of a resident transposon, or a DNA sequence introduced by the methods of this invention, is a relatively simple matter which can be accomplished by restriction enzyme digestion and gel analysis. In complex situations, Southern hybridization may be necessary. When a resident transposon is identified at a desired location, a genetic construct of this invention is introduced using any '20 appropriate method. Homologous recombination will occur at some frequency and those cells in which recombination has occurred can be detected, for exampie, by Southern hybridization.

The invention is fu'ther illuvtrated by the follWing Examples.

0O

EXAMPLES

Methods Bacterial strains and bacteriophaqe The following abbreviations are used throughout this application when V0. referring to drug resistance: kanamycin resistance Kan

P

kanamycin resistant Kan

S

kanamycin sensitive Kan ampicillin resistance Amp 20

R

ampicillin resistantAm ampicillin sensitive Amp S chloramphenicol resistance CM R chloramphenicol resistant Cm R ~chioramphenicol sensitive

C

tetracycline resistance Tot R tetracycline resistant Tot R tetracycline sensitive Tet 8 The following strains were deposited with the NrR~L, Peoria, Illinojs, on July 12, 1990, under the terms of the Budapest Treaty: coli JX1O3/pPX1575 accession #NRRL B-184 72 E. coli XC1O61/pMC91 APBlOO accession #NRRL B-16673 EB. coli MC1061/pMC9, APB103 accession #NRRL B-18674 coll C600/F1 tslac::nlO...acce~ssion #NRRL 1 -3,675 E. coli JC1553/F112 was obtained from Dr. B.

**Bachm;*nn (Coli Genetic Stock Center, Yale Universz'ty) **and has the genotype: ArcgG6, RetBl, his!-1, ei6, .'20reaA7, A~ji2, Xy17, cral6, LacYl, gpsLI04, Qi3A2, tsK A sup044. F112 carries an intact A rectptor 0* (lamB) and gelies for maltose utilization (Mal other E. coli strains used in construction of plasmids and recombinant A phago are as follows: Y1088 2S (klaU169 spUpE _pMF hsR hsdM+ metB trpR jonh~2l IroC::--Tn (pXC9) [ATCC 37195)) was used as host strain in recoverinQ receinbinant A lysogens (Young and Davis,, S~Jience 222:778 X1b~~ C1061 [ATCC 51338] (Aara-leu) OP *7697 4aJaPOZY) X74 hsdR hsOM+ graD139 _qglEl5 .gKi(, MpL) was used also as a host for some of the recombinant A phage and for titering A stocks (Moissner: et Proc. Natl. Agd Si USA 84:4111 (1987)); UiM1O3 If too +1Q too CATCC 39403] (P'traD3U _rA laci~ MlS/A.pro-lac) suDE hpdR AbcB15 -hi-l end.Al was used as a host ~strain for construotion of plasmids contain~ing tao or ac-prcmoter regulitted genes (M~essing 9 Al., ggl 21. Acids Res. 9:309 (19821)); N99cI (F3'ca1K2 rpsL A- cI is a host strain containing tine wild type cI repressor gene, but heavily dtaleted for other A functions (Gottesman et al., ~.Mol. Biol. 140:57 (1980)); C600 [ATCC 47024] (F thi leuB6 lacYl thr-l hsdR suDE44 tonA21 A) was used as a host strain for the temperature sensitive F factor, F tslac TnlO; and KBT001 Ip3uE LacY IyvsA leuA, iProC metE ArgrI rpsL was used as described in the Examples (Kadner and Liggins, J. Bact.

115:514-521 (1973)).

The bacteriophage A cloning vehicle. Agtl [A'TCC 371.94] (cI857 nin5 laoS Sam 1.00 4shnd 11161 A2-3 iirIA3 0 SrIA4 -0 rIABO) was maintained in Y1069 (Young and Davis, Drop-. Natl. Acad. Sci. USA 80:1194 (1983)).

The cloning vehicle A-NM816 Cj:-a 2 clts ni.5 lac5) was maintained as a lysogen in A1089 (Murray, In:LAI4BDA II(1983), Hendrix et al., eds., Cold spring Harbor of-be Labo~ratory, NY, p. W9).

C Attenuated Salmonella vaccine strains used 6.0.020 were: Ty523 (AroA zs407 his.G46), a derivative of S.

0:60typhi CDC 1080 Patent No. 4,735,801]; SL3261 .680 *,rqA554::TiilOTc a stable non-reverting arA deletion der-Ted from S. tvyhimurium, biotype Wray; and SL2.438 [ATCC 39184] (h~iAG46 aroA 554 TnlO Tc an a~7oA deletion mutant of S. dublin.

S. typhimurium LB501.0 is a galE mutant ~:.~':derived from LB5000 (Bullas &Ryu, J. Bacteriol.

.15:471 (1983)). The lamB receptor of E. coli w~s introduced into LB5010 by mating with E. coli KL188 R R containing Pll2dTnlo(cm), selectiaig for CmR The CmR F11.2 was obtained by transforming F112/JC1553 with plasmid pNK1210 (Way et al., Gene 32:369-37A, (1984)), and selecting Cm. exconjugants of PR (RUp13, gn19 C

,C

malB:described by Hautala et (Proc. Natl. Ag.ad., 8ci. 76:5774-5778 (1979)) which were sensitive to 22 The marked lamB prime f actor was moved into a multiply auxotrophic E. coli strain (KL188 (thil, pygD34, his6al, p95, Mtl,2, xyl7, malAl, rpsL118, A R A, obtained from B. Bachmann, Coli Genetic Stock Center, Yale VJniversity, which was counterL.'ilected in a sv0-sequent mating with S. y ~himurium LES010 by omission of histidine, uracil, and thymine from the minimal media supporting growth of LB5010. The lainR pzime factor was moved into attenuated vaccinae strains of Salmonella by mating with counters el1ecting the donor strain in a defined media containing all amino acids with the exception of isoleucine, valine, methionine, and leucine.

Haempilug influenzae Rd strain HDGB5 (Deich and Green, J. Bacteziol 170:489-498 (1988)) was used as described in the Examples below.

Bordetella pertussis, strain BP'A' discussed below in Example 6, is an FHA isolate of B. pertussis, obtained from Dr. Stanley Falkow, Stanford University, Pal1o Alto, California, having wild type pertussis toxin and hemolysin production.

Media forGrowth of Bacteria

O

j, S. typhimurium, g. dubin, and S.

typhi strains were cultured in L broth. Haemoghilus influenzae cells- were grown in Brain Heart Infusion 600st-broth containing 10 M&g/ml hemin and 2 Ag/ml NAD. When 0 a. a.*appropriate, ampicillin was present at 100 micrograms per ml and Janamycin was present at 50 microgra~s per ml. R~tussjq strain BP370 (FHA- TOX was propagated from freezer stocks on semisolid Bordet-Gengou (BG) blood agar (Kimura, A. et Al. Infect. Immun. 58Q:7-16 :09 (1990)). Bacterial mass from agar medium was inoculated into CL medium for liquid cultivation. (Imaizumi et al., Infect. Immun. 41:1138-1143 (1983)).

For inoculation of mice with live Salmonella typhimurium SL3261. derivatives, bacteria were gr.)wn in 23 a defined medium consisting of per liter: 6 g Na 2 HPO4, 3 g KH 2 PO 4 0.5 g NaCi, I g IqH 4 C1 adjusted to PH 7. 0 and further containing 2 g f-Glucose, 0.2 g MgSO 4 1 M sodium citrate, 5 g of vitamin-free casamino acids, Mg 20 niootinic acid, 10 mg dihydroxybenzoic acid, mg para-aminobenzoic acid, and 35 mg each phenylalanine, tryjptophan, and tyrosine.

Mice were orally inoculated with up to 10 bacteria by direct intubation into the stomach with a blunt-ended needle. Bacteria grown as above were centrituged, washed, and resuspended in 1.5% sodium bicarbonate.

Genetic Methods Plasmids were transformed into E. coli strains or S. typhimurium LB5010 by the CaCd method (Dagert and Ehrlich, Gene 6:23-28 (1979)).

Bacteriophage P 2 2 HT intlO5 was used for generalized transew.ction of genes from S. typhimurium *LESOIO. LB501O was sensitized to pliage P 22by induction of LPS synthesis by inclusion of 22.la-toei 090 the growth media of a log phase culture for one hour 64060 '0960"prior to phage infection for production of phage lysates. P 2 2 phage prepared on LB5010 were mixed at a multiplicity of infection of I. with SLA3261, SL1438, or Ty523 and transductants were selected on suitable too**:medium.

Oligonucleotide synthesis Oligonucleotides were synthesized on an :9:9:Applied Biosystems (Foster City, CA) 380B DNA synthesizer using f-cyanoethyl phosphoramidite chemistry.

Expression of Genes oxignicLT-B is the non-toxic subunit of enterotoxienicE. coli labile toxin (LT) and was expressed 9 in E. coli.JM103 in a pUCS vector by cloning a 590 base pair EcoRl-HindiII fragment into 'ScoRl-HindIII sites of pUCS. The full length Plasmodium, bercghei CS protein 24 was expressed in a PL promoter expression vector and consisted of the entire coding sequence plus 8 amino acids (Met-Glu-Ala-Leu-Ile-Leu-Asp-Lys) at the amino terminus (Fig. The first seven amino acids are derived from the expression vector and a linker and the lysine is derived from the Dral site located one codon upstream from the CS protein coding region.

Electrotransfer Methods for Antigen Detection Heterologous recombinant protein synthesis was detected in E. coli or Salmonella cells by transblotting protein samples separated by polycrcylamide gel electrophoresis onto nitrocellulose membranes, blocking with 0.5% Tween-20 in PBS, followed by antibody binding in 0.1% Tween-20. Bound antibody was detected with horseradish peroxidase-labeled Protein A (Kirkegaard and Perry, Gaithersburg, MD). For detece tion of LT-B antigen, the primary antibody was goat a-LT-B polyclonal reagent partially purified by eluting bound material from a Sepharose 4B protein A affinity *:so column.

Electrotransformation of Haemophilus Influenzae Haemophilus Influenzae cells were grown in BHIxv medium to mid-log phase (OD600=0.3) at 37°C.

Cells were pelleted, washed twice with 10 mM Hepes, pH7.0, 20% w/v glycerol and resuspendcd in 1/100 volume O1mM HEPES pH7.0/20% glycerol. Plasmid (pPX1575) DNA was added to -lo g/ml and cells were electroporated with a BTX Transfector 100 electroporator, Call suspension (-50 microliters) were diluted into 1 ml r* BHIxv media and grown for 2 hours at 37 C to allow expression of the transduced marker. Cultures were 45 then serially diluted in BHI and plated on BHIxvkanamycin (20 g/ml) selective agar and incubated at 37 C.

25 h) Electrotransformation of Bordetella pertussis. Starter cultures of BP370 in CL medium were incubated overnight at 35-37oc and then inoculated into 1.3 liters of CL medium and incubated with shaking for 18-24 hours at 35°C. Cultures were harvested by centrifugation at 5000 x g for 30 minutes in a Sorvall GS3 rotor. The cell pellet was reiuspended in 200 mls of 0.001 M HEPES buffer, pH 7.2, and subjected to 2 more successive rounds of washing in 0.001 M HEPES buffer. Finally, cells were resuspended in 20 mis 0.001 M HEPES buffer containing 12% glycerol. Cells were frozen and retained at -70 0 C. During washing operations, cells were maintained at 0 0 C. For electroporation of DNA, an appropriate amount of DNA (up to pg) was added to 450 il of a thawed cell suspension and mixtures were subjected to an electrical pulse of 33.6 Kilovolts/cm 380 microseconds in duration. Immediately after electroporation, cells were diluted in 1 ml of 0 unsupplemented CL medium and incubated at 37 C for one 4* 20 hour before plating onto BG blood agar plates containing either 25 pg kanamytin per ml or 50 pg ampicillin per ml.

i) Southern Blotting of Chromoso~al DNA of S. Typhimurium.

A chromosomal DNA was prepared l'rom 5 ml overnight cultures of candidate clones by lysing bacteria in 600 pl of TE containing SDS tlnd 100 ig proteinase K per ml. Cell wall debris andl polysacchmrides were removed by addition of 1% cetyltrimethyl amrjonium bromide (CTAB) in 0.7 M NaCl at 65(00 followed by extraction with chloroform/isoamyl alcohol. Chromosomal DNA was precipitated with isopropyl alcohol, 4•* pelleted, dried, and redissolved in TE. Chromosomal DNA was digested with appropriate restriction enzymes and the restricted DNA was subjected to electrophoresis oj 0.6% Agarose and transfer to nylon membranes.

26 DNA probes were prepared from CsCl purified plasmid preparations by labeling by random primed incorporation of digoxigenin-labelled deoxyuridinetriphosphate. Hybridization conditions were developed according to procedures described in Molecular Cloning (Maniatis, T. et al., Cold Spring Harbor, 1982).

Detection of the digoxigenin-labelled hybridized DNA was according to the supplier (Boehringer Mannheim).

EXAMPLE I Construction of Plasmid Vectors Containing Modified Transposition Functions As shown in Figure 2, pNKl210 was used as a parental plasmid vector in the creation of a construct to insert a DNA sequence an expressible gene) stably into the chromosome of gram negative bacteria.

pNK1210 contains a tac promoter controlled transposase, «*9P the inverted repeats oY TnlO and a gene encoding chloramphenicol acetyl transferase. pNKl210 was 20 derived from pNK861 (Way et al., Gene 32:369-379 R9 (1984)) by replacement of the Kan determinant with a 1Z75 bp fragment carrying the CmR gene from Tn9. The construct was modified by removing the natural inverted repeats of TnlO and replacing them with an oligonucleotide specifying an inverted repeat sequence comprising I the terminal 31 base pairs of the right-end of TnlO flanking a single cloning site (Fig. 3A) to yield plasmid pPX1569. A second oligonucleotide linker (Fig.

3B) was inserted to yield a plasmid with several cloning sites (pPX1572), which was further modified by inserting a KanR determinant of Tn5 into the Xhol site of pPX1572. In this configuration, genes inserted into cloning sites flanked by the inverted repeats can transpose in the presence of active transposase.

A mating assay was performed to verify that the 31 5 base-pair synthetic oligonucleotide-derived 27 inverted repeat sequence of pPX1575 acts as a substrate for transposase and yields transposition events.

pPX1575 was transformed into F112/C600 which was subsequently mated with E. coli KBTO01 following induction of transposase functions with IPTG. Se-

R

lecting Mal or Kan exconjugants of KBT001 revealed that approximately 10 Mal+ exconjugants were also R S R Kan and Amp and 100/100 Kan exconjugants were Mal.

A similar experiment conducted with F112/C600 transformed with a similar vector lacking the inverted repeat sequences yielded Mal but not Kan R exconjugants. These results indicate that the Kan determinant had transposed onto the F factor and the 31 base-pair inverted repeat, as expected, is a substrate for transposase.

EXAMPLE 2 Bacteriophae A suicide Vectors for Transposition in Salmonella 20 Suicide delivery, as used herein, refers to *the introduction of a transposon via a DNA construct which cannot replicate in the recipient. ColE1-, and pSClOl-based plasmid vectors replicate freely in S. typhimurium and most other salmonella species. As such, these vectors are not suitable for suicide delivery of modified transposons in Salmonella.

On the other hand, bacteriophage A will not undergo lytic growth in Salmonella unless nusA, a wild type E.

coli host function which is required for A N proteindependent antitermination of lambda DNA transcription, and lamB, which is required for A phage attachment, are present. In addition, A phage does not lysogenize S.

typhimurium because of a requirement for the nusA gene product (Harkki, Mol. Gen. Genet. 209:607-611 (1987)).

Thus, A phage vehicles are not propagated in salmoprell, and can be used as suicide delivery vehicles for 28 transposon mutagenesis of this host if the IlrnB gene product (the outer membrane receptor for phage A) is provided. As shown below in Table I, a series of bacteriophage strains derived from either of the widely studied Agtll 15 strains or ANM816 was tested for ability to form plaques undergo lytic growth) on several Salmonella strains which carried the P112d~nlO(cm) conjugative plasmid. Although capable of forming plagues on E. coli strain MClO06l, none of the phage was capable of forming plaques on a variety of Salmonella strains. It is not understood why the phages (all of which carry the ninS deletion) do not form plaques on lamB Salmonella (Harkki et al., Mol.

Gen. Genet. 209:607-611 (1987)). Modified ve3rsions of these bacteriophage carrying transposase recognition sequences and transposase functions can be used as suicide delivery systems.

4 TABLE 1 20 Efficiency of Bacteriophage A Plaguing on Salmonel~la and R. coli S. S. S.

E. Coli F132cm/ F112CxM/ Pll2CMV MClO61. LE5O1O SL3261T52 SAgt32 I x 10 10 <20 <20 ANM816 1 x 10 10 -<20 <20 3 9 **:APB100 3 5 x 10 <20 <20 APB103 1 7 x 10 9 <20 <20 AP1534 3 x 109 <20 <20 A PB107 1 2 1 x 109 <20 <20 29 Notes: 1 Derivatives of ANM816 2 Specialized transposing and transducing phage for P. berghei CS protein Derivatives of Agtll 4 Specialized transducing phage for LT-B Both A phages described in Figure 4 were modified to contain a transposase function and TnlO inverted repeats flanking a selectable marker. APB100 was constructed by cloning a 5.2 kb EcoRI fragment of DNA from pNK1210, containing a tac promoter controlled transposase gene, the inverted repeats of Tnlo and a chloramphenicol acetyl transferase gene into the EcQRI site of Agtll. Cm lysogens were selected in E. coli Y1088 in which the transposase is repressible by the laci gene product contained on plasmid pMC9. APB100 *.e can accommodate the insertion of up to 2 kb of extraneous DNA.

20 APB103 was constructed in an analogous fashion by subcloning a 5.2 kb EcoRI fragment of pPX1575 containing the tac promoter controlled transposase, a 31 base pair inverted repeat derived fromi TnlO flanking a Kan determinant from Tn5 and a multiple cloning site, into EcoRI sites of ANM816, resulting *1 in replacement of the lac UV5 stuffer fragment. Kan lysogens of MC1061 (pMC9) were selected. APB103 can *4 4 accommodate up to 7 kb of extraneous DNA.

Such A phage vectors, which contain the transposase gene outside the inverted repeats which are the substrate for site specific recombination and transposition, will act not only as temperate transducing phage particles in E. coli, but will catalyze transposition of any DNA an expressible gene) contained within the inverted repeats. Since the transposase gene is outside the inverted repeats, the 30 insertion can be stabilized. Because such phage vectors cannot be propagated in Salmonella lamB+ or other lamB+ recipients, either lytically or as lysogens, the phage and consequently the transposase protein is diluted out through the process of cell division. As the concentration of the transposase protein decreases, any transposon which has transposed from the phage to the bacterial chromosome will be stabilized.

A DNA sequence an expressible gene) can be introduced between the inverted repeats of bacteriophage vectors such as those shown in Figure 4.

One way in which this can be accomplished is by plasmid-phage transposon exchange as shown schematis1 cally in Figure 5. A DNA sequence an expressible gene' is cloned into a plasmid vehicle pPX1575) such that the selectable marker and the expressible gene are flanked by the inverted repeats.

t In a host cell, lysogenic for a phage of the type "20 depicted in Figure 4, site specific recombination or transposition between the inverted repeats of the plasmid and the lysogenic phage will result in a proportion of the lysogens containing the expressible gene and the selectable marker from the plasmid. The small proportion of phage carrying the exchange event can be selected in E. coli hosts by selecting for lysogens carrying the selectable marker originally

O.

associated with the plasmid. The unselected express- Able gene is linked with this marker.

EXAMPLE 3 Plasmid/Phaqe Exchange of an Expressible E. Coli Gene Flanked by Transposase Recognition Sequences LT-B can be expressed in Salmonella species and has proven to be immunogenic in mice when expressed and administered in live attenuated vaccine strains of 31 Salmonella (Clements et al., Infect. Immun. 53:685-692 (1986)).

Figure 7 illustrates the construction of a transposable genetic cassette carrying a DNA sequence encoding the 11,000 dalton B subunit of enterotoxigenic E. coli heat-labile toxin The gene specifying the non-toxic subunit was localized on a 600 base pair EcoRI/HindII fragment in pPX100 in which LT-B expression was controlled by the lac promoter, the sequence of the gene corresponding to the data of Leong et al. aInect. Immun. 48:73-77 (1985)). An 800 base pair HaeII fragment containing the LT-B coding sequence and the lac promoter was subcloned into the BamHI site of pPX1575, which had been blunt-ended by the action of the Klenow fragment of DNA polyinerase I. APB103 was integrated into JM103 containing the LT-B transposition plasmid pPX 1S79. The resulting lysogen was induced to transpose by the addition of IPTG and phage particle R s production induced by temperature-shock. Kan Cm lysogens of JM103 were selected.

R

e,6: Approximately 25% of Kan transductant clones b# were also Cm

R

suggesting that they were either double lysogens or contained single lysogens harboring both.

Kan Cm clones were considered to have arisen by exchange of genes flanked by the inverted repeats with inverted repeats of the APB100 lysogen. Although the Kan R determinant was used to select for putative exchange, all of the Kan R clones also expressed LT-B by colony blot analysis following IPTG and temperature induction. This result suggests that the unselected gene expression cassette (LT-B) co-transposed as i* predicted with the drug-resistance marker. One of the resulting KanR lysogens was chosen and phage obtained by induction at 42 C. The resultant phage stock (APB105) was used to infect S. typhimurium and S.

typhi. As discussed previously, such a construct 32 serves as a suicide delivezy system. The construct cannot 1 e propagated, lytically, or as a lysogen, in salmonella. However, the transposase gene will be expr:essible and as described in Example 4, the LT-B gene can transpose with the genetic cassette, to the Salmonella chromosome.

EXAMPLE 4 Transposition in salmonella a) selecting Wransposition Events in S. typhimurium and S.-typhi Accoiding to the general scheme shown in Fig.

8, several specialized transducing phages were used to transduce S. typhimurium Fll2dTnlO(cm/LBSOIO (lam~a+) Or S. tvphi F112dTnlo(cm)/'TyB23 to drug-resistance. Table 11 shows the results obtained using APBIOS. PteqUency a. of transposition was determined by enumerating KanR Salmonella colonies following infection with transducing A phage. APB105 was mixed with 2X10 8 a recipient *Salmonella cells at the indicated m.oi., which had been grown to luidlog p~hase in the presence of maltose to induce the bacteriophage A receptor. Infected cells were incubated for 1.5 hours at 37 0 C to allow expression of Kan Rbefore plating.

As shown in Table 11, drug-resistant S.

typhimm4 X. were ci)tained only in the ja bu+o bu o lamB S. typhimurium. For each of tht, A phages, drug-resistant. clones arose at frequencies of up to 10- at an m.o.i of 0.2 active phage particles in S.

typhimurium Fll2dTnlO(cm)/ LB5010 and with a lowex frequency in S. typhi Fll2dTn(cm)/Ty523.

'A'2 TABLE II Transpog1.tion tz Salmonella Using Specialized Using, Speciallzed Transposing Phages Carrying Reverolog(Iu*k Gene Expression Cassettes Donor Bacteriophage ,Recipient: Salmonella S rain* Fl2L2cx/ V'Nhl2cm/ LB5010O LB5010 TyS23 _Xy523 M~o.i. 2 4.01&_6 -ll'8 5,240'7 <X 8 in,o,i, 2 l'OXlO_ <bclO' 4.x10" 7 <1x10' 8 MInO'i. -2 1.2X10, 6 <1XIO-8 LOXIO'8 <Xl0_ 8 no phage 1.040" 4 <10, 8 IO1 8 <1x10_ 8 b) Characterization of Chromosomal Inserts Kan Rclones of S. typhimurkw'i LB501.0 (lamB' arisinq following infection with APIlOS were characterized for expression~ of the unselected marker and for dotoosomal location by southern blot analysis, a Southerit blot of Znnl digested cbiromosomal DNA probed bictlinylated PPX1579 DNA revealed that each of the iXan Rclorkos had arisen frc- s eparate transposKItion S.,events, s~nce each clone had a single copy of the transposon at random loci in the typhimuzrium chromogome. Further, eamih twr 'in lones expressed the LT-.B antigen as deterzined by 'Western blot analysis.

Expression of the LT-D antigen is cDntrolled by the Lac lot UVS promote,- wbicli Is uncontrolled when Jintroduced into SaqlmoarqlA which arb deficient in lactoso mata*.,-li zing genes. one wlone in particular expressed more antigen than the rem~3.ning 9 analyzed clones, suggesting that there may be positional effects on the expression of foreign genes integrated at random in the Salmonella .:chromosome.

34 c) vaccine strain, of ittenuated Salmonella 8xPress_%ipnc Intectrated Genges S. typitl~urium LT2 derivative LBSOIO is a laboratory strain of Salon~1la which has some convenient features for manipulat,.n of genes in Sal 2~.

LB5010 is trans f cmabl e at high frequency with plasmid DN4A and, because o~t its restriotion deficiency, can accept DNA propagated in Esaherichia coli. However, it is not itself a vaccine oandidate strain. To create vaccine candidates of live attenuated Salmonellaf phage P22 HT intlO05 was propagated on Fll2d~nl0(cm)/LB, OlO derivatives containing modified transposon expressinig LT-B and used to transduce several species of aroA deficient SalUonellz to KanR Transductants of S.

~typhi Ty523, Aublin SL1438, and S. typhimurium SL3261 were obtained. Each of the transductants of the different species were demonstrated to express LT-B and I1urthor, if the locus at which LT-B was integrated in LBSOlO yielded enhanceO expressi:;n of the antigen, enhanced antigen expression was also observed 1i the #Poo tranaductants. This indicates the likelihood of *01o 0 trAnsduction of the inserted LT-B expression cassettes, which depo~ads upon homologous recombination, into identical loci in o",her species ot Salmonella.

As an alternative delivery system, the LT-'E transposon was integrated into several -Salmonella a:V species using temperature-sensitive FP factors.

romperaturesensitive Pt ,'Actors replicate in a liniite4 number of gram-negative bacterial species, including Sgam.n~a.lA at low temperatures but fail to replicate at high temperatures. Temperaturd-se.16itive PI factor 4gw containing an, intact TnlO to supply the transposase 0function, the lactose operonf and the Kan R LT-B transptoson, was isolated in paAli and then was introduced into S. typhimurium LU5OlO by mating from coli and selection for Tat R and lactose utilI zation at low 35 temperaturo. The Kan RLT-B transposon was constructed first in E. gpj i by transforming an F-'t lacTnlO strain with plasmid 'RX157J. 'Transposition of IT-B to the F' factor was jxnduced kith IPTG and ijan R TetR,. Laoc+ exconjugants wer,) :edin a mating, vwh p. scli KBTO0l. The F' t lacTnIO carrying t:-e defecti-Ve LTI-B transposon was subsequently introduced into s.

tynhimu 7 um LB5OIO ,j mating. The F' factor in S.

t. irurim LB5010O was then introduced into S.tMh Ty523 dublin SLl438), and S9 typhimurium SL3261, bly mating selecting for Kan R Tet L T40c exconjugants and coounterselecting against the LBSO1O donor strain. LT-B transposition events were selected in each of these strains by selecting Lac-, Ktan RO Tots colonies followilig 40 generations of growth ir, br~~th lackcing drug se~fectlon at high temperature (42 0 All of the R a Ran Tot p, Lao- colonies,, wihich Were presumizd to have lost the F' factor by segvcegav ion, Oztpressed IWT-B as determined by colony blot cr LT-B antigen.

20 Transposition of the modified ransposons from the e 00 's *temperature-sensitive F factor is dependent upon the ,~transposaso supplied by the TnlO also 1-catji.O on the F factor.

d) Stability of Tlrnsposition The modified transptsons do not retralispose to other loci because thc transposast funo~tiohi which is normally encoded within thie right 44nverted repeat of as. A111O, are absent. Further, transposition in salmonella is stable since no 183.0 elements no constituent transposase genes), which hav4 bieen detected in nuiner- 0 i ous E. cli strins, havo ever been detected in Salmonella typhimurium (Klecknier et al., Mobile DNA, ASI4 Publications, Washington, D.C. (1989)). In addition, stable transposiftion events will result ir, gene expression which should be inherently stable when 36 compared to plasmid born copies of the same gene, which ray be lost in absence of positive selection due to natural segregation of the plasmid or due to selection for loss of the plasmid because of deleterious effects of gene expression.

To test stability of LT-B expressing transposons, one SL32\51 isolate, A3 isolated by P22 transduction of Kan segregants from F112dTnlO(cm)/LB5010 (A3) was grown in L broth lacking kanamycin for 40 generations as shown in Table III. To compare, pPX10/SL3261 (a pUC8 plasmid derivative expressing LT-B) and pUC8/SL3261 were also grown without ampicillin selection for 40 generations in LB.

In the first example, from cultures of SL3261 (A3), 100% of the colonies arising on LB agar medium were Kan and expressed LT-B antigen; likewise,, there was no difference in the number of colonies recoverable by plating directly on LB containing kanamycin or lacking it. On the other hand, only 3% of the colonies from

O

20 the pPX100/SL3261 culturu arising on LB medium follow- ,0 ing 40 generations of 4cowth without drug selection were and by di:act plating only 3% of the colonies able to grow on LB agar were recoverable on LB agar containing ampicillii. Further, there was no apparent decrease in gene expression of LT-B in cultures of A3 *oo relative to pPXlOO/SL3261. This indicates that the transposition event yielded stable expression without selection under culture conditions in an attenuated vaccine strain of Salmonella.

*S 3

*S

37 TABLE III Stability of LT-B Expression Plasmii versus Chromosomally Integrated LT-B Retert.-ion under Culture Conditions after 40 Generations ,acterial Strain of Passagre Expressincr LT-B) Defined Defined Medium Medium Drugr pUCB/SL3261 95% 100% pPXIOO/SL3261 3% 100% SL3261A3 100% (100%) 100%00 e) Stability of Gene Exp ression of Vaccinp Strain of 15 Salmonella Containinr LT-B Transposon e0g #see An isolated transductant of SL3261, an aroA *vaccine strain of S. t'.!himurium, wan, examined for Tcatention of LT-B expression after immunizing Balb/c 0:00* mice with a single dose of 10~ bacteria per os (orally). As controls, separate groups of mice were orally immunized with either 10 9 pUC8/SL3261 or 10 9 pPXlOO/SL3261. Almonella were cultured from isolated liver, spleen, or lymph node homogenates obtained from immunized mice and the proportion of pl1asmi d- containing organisms or stable transposon- containing organism was determined, 66:0 wrobAs shown in Table IV, Very few Salmonella 00 0wereobtanedfrom tissue nomogenates of mice immunized with either pUQ8/SL3261 or pPXlOO/SL3261 and of those only a small percentage were demonstrated to contain *see plasmid of the original vaccinating dose. Several lymph des surrounding the intestine were dissected from each of the vaccinated animals on day 10 or day IS following oral vaccination of Balb/c mice with bacteria. Lymph node saiples were homogenized and duplicate sam31es plated on LB or LB+ selective drug 38 medium. In addition, the proportion of drug-resistant colonies was determined by replica plating colonies arising or non-selective medium. On the other hand, mice immunized orally with 109 SL3261(A3) contained Kan R organisms on days 3, 10, and 15 following vaccination. Further, 100% of the bacterial colonies obtained by plating organ samples on nonselective medium were KanR and random testing of 20 KanR isolates showed expression of the LT-B antigen. These results demonstrate that integration of a single copy of an expression cassette encoding an antigen can stabilize expression relative to plasmid-borne copies of the same expression cassette in the context of a live vaccine strain of Salmonella.

0005 0 0 :TABLE III 0. 0 0 0. Stability of Integrated Forms of LT-B Following Oral Vaccination of Mice Vaccine Day 10 Day Strain Animal Total DrugR Total. Drup,R t pCUS/SL3261 1 2 2 100 1 1 100 2 0 0 0 0 3 1 1 U0 158 3 2 %40.5 pPXlOO/SL3261 1 3 3 100 59 0 0 2 2 36 0 0 44 0 0 3 360 0 0 0 0 SL3261A3 1 612 612 100 0 0 2 360 360 100 103 103 100 30 3 456 456 100 102 102 100 o00 "06 f) Transposition of Expression Cassettes ContaininQ Alternate Promoters and Gene Reulatory Signals The method used in the example presented above for stable integration of an LT-B antigen can be generally applied to other proteins whose expression is 39 controllable by various gene regulatory signails which can enhance levels of gene expression. To provide several examples of the utility of this melthod for creating gene insertions for either protein expression or use in a live vaccine strain of salmonella, gene expression cassettes containing the strong leftward promoter of bacteriophage A (PL) were incorporated into pPX1575 and Kan R derivatives of APB104 were obtained by plasmid-phage Tn exchange.

Likewise, as shown in Figure 6, the protective surface antigen (CS protein) from a murin<i malaria parasite, Plasmodium berqhei, was expressed in a PL expression vector. A series of plasmid const ucts was performed in which the entire coding sequence of the P.

berhei CS gene was inserted into the PL promoter expression vector rPXi600. The gene sequence for the SP. berchei CS protein is according to Eichinger et al.

(Mol. Cell. Biochem. 6:3965-3972 (1986)). The cassette for the expression of the CS gene was contained 20 on a 2.3 kb BamHI restriction fragment lWhich was subcloned into BamHI site of the transposition vector pPX1575. The resulting plasmid was transforied into a host strain lysogenic for APB104. APB104 wlls derived from APB103 by exchange with CmR of PNK12'O. Phage

R

particles which had exchanged the plasmid located Kan R Cm

S

determinant wetre selected as Kan, Cm lysogens which carried the etpressed CS gene. The CS protein incorpo- 66 rated into pPX1575 yielded APB107.

To obtain host E. coli strains iIli which both 30 the PL promoter and the lac UV5 promoter are repressed, either plasmid pMc9, which contains the laigi gene in a pBR322 plasmid, was transformed into E. cpgli N99cI or Agtll was lysogenized into JM103 or JM109. Initial plasmid constructs for expression of the j1 berghei CS in pPX1575 were recovered in E. coli JM03 (Agtll) to control both expression of transposition functions by 40 the tac promoter and possible deleterious effects of the PL-promoted expression of the CS protein in E.

coli. pPX1575 derivatives harboring expression cassettes of the CS protein were lysogenized with APB103 to create a strain doubly lysogenic for Agtll and APB103 for the exchange reaction. APB103 lysogens of JM103 would not be suitable hosts to repress the expression of genes controlled by the PL promoter because APB103 contains the phage 21 immunity region.

The double lysogens were induced for phage functions by temperature shifts of candidate cultures and KanR lysogens were selected in N99cI+ (pMC9). Lysogens which were Kan and Cm were retained as candidates and were presumed to have arisen by exchange of plasmid-born PL expression cassettes and selectable markers flanked by synthetic inverted repeats with the inverted repeat region of APB103.

g) Bacteriophage A Cloning Vehicles for Directly 20 Generating Specialized Transposing Phaqe Lines *o Derivatives of Agtll and ANM816 are created which are suitable cloning vectors for the generation of A phage which can be used directly for insertion of expressed genes into chromosomes of other organisms *25 using standard splicing techniques rather than lysogenplasmid transposon exchange. This is accomplished by subcloning the laca region of pUC18 into the BamHI site oof pPX1575, followed by cloning a linker into the XbaI site of the PUC18 polylinker region. Such linkers may 30 encode the in-frame readthrough of the laca peptide and, for example, any or all of the NotI, Sfil, and SpeI restriction enzyme recognition sequences which are not otherwise present in bacteriophage A. The modified pUC18 polylinker region may be subcloned as a 400 bp HaeII fragment into the filled out BamHI site of pPX1575, By exchange of this modified pUC18 region 41 into APBloO (a Agtll derivative) or APB103 (a ANM816 derivative), A cloning vehicles are generated such that antigens or proteins can be cloned into any of the three unique cloning sites using suitable adaptors or linkers by screening either for expression of the protein or for insertion of cloned DNA by interruption of the laca function in a JM103 or JM109 genetic background, provided that the hfl mutation allowing for high frequency lysogenization is also present. The resultant phages can be used directly for constructing unique live vaccine strains without the necessity of separate expression steps.

A bacteriophage lambda similar to the ones described above was isolated and characterized. Bacteriophage APB113 was isolated by plasmid-lysogen exchange as described above using pPX1591 as the plasmid vehicle and APB104 as the lysogen. Bacterio- 0 phage APB104 was derived from APB103 by exchange of 0. kanamycin-resistance with chloramphenicol-resistance.

TN10 transposase controlled by the tac promoter located outside the inverted repeats of TN10 which flank the chloramphenicol acetyl transferase gene. Plasmid pPX1591 was isolated as follows. A 400 base pair Haell fragment isolated from plasmid pUC18, blunt-ended with T4 polymerase, was cloned into the klenow-enzyme treated BamH1 site of pPx1575. This intermediate veco tor, termed pPX1577, contained the laca peptide and the multiple cloning site of pUC18, a kanamycin-resistance 30 determinant, flanked by the synthetic 31 base-pair inverted repeats of TnlO. This plasmid was digested with Xbal and the double stranded oligonucleotide linker, shown in Figure 9, was inserted.

This oligonucleotide, when inserted in the orientation shown in Figure 9 in the XbaI site of 42 pPx1577, yielded a plasmid which contained a functionally active laca peptide which complemented the deletion of E. coli JM103. Colonies that had the oligonucleotide linker in the opposite orientation yielded a non-functional laca peptide. The resulting plasmid, termed pPX1591, contained unique NotI and Sfil restriction enzyme sites and in addition regenerated a unique Xbal site at the 3' end of the linker. DNA sequencing using standard M13 primers revealed that the inserted oligonucleotide was present as indicated. To isolate APB113, E. coli JM103 containing pPX1591 was infected with choramphenicol-resistant APB104 at 300C in log-phase broth cultures induced for the lambda receptor by inclusion of 0.2% maltose. When cultures had reached late-log phase, they were induced to lyse by temperature-shock at 42 C. The resulting phage ;o lysate was used to infect a fresh culture of JM103which was subsequently selected for kanamycin-resistant lysogens which formed blue colonies on LB agar medium 20 containing 200 micrograms X-gal per ml. A lysogen 0 which transduced kanamycin-resistance at high frequency was termed APB113. DNA isolated from this bacteriophage contains NotI and SfiI sites which are unique to bacteriophage lambda. Thus, APB113 has *25 properties which allow cloning of DNA fragments as large as 7 kilobases into the unique NotI and SfiI sites, which can be screened in kanamycin-resistant lysogens as white colonies on medium containing X-gal using an E. coli host carrying a laca deletion.

Further, the lac promoter can promote expression of the cloned inserted DNA if the inserted DNA is In the correct reading frame with respect to the laca peptide and has the appropriate initiation signals. The phage have the additional property that the cloned DNA inserts are essentially transposable elements such that 43 expressed DNA inserts can be examined by stable integration into a bacterial host chromosome.

An E. coli JM103 lysogen carrying bacteriophage APB113 in has been deposited with the 3 National Regional Research Laboratory (NRRL) culture collection on 19 August 1991 and has been given the Accession No. B-18871.

Transposition in Haemophilus influenzae Transposition of Kan from pPX1575 was tested in H. influenzae d strain HDG85. This plasmid should act as a suicide delivery system in H. influenzae, as colEl derived plasmids have been shown not to replicate in H. influenzae cells (Danner and Pifer, Gene 18:101- 105 (1982)). Plasmid DNA was introduced into H.

influenzae cells via electroporation and KanR recombinants were scored. As summarized in Figure pPX1575 (-10 micrograms) was added to H. influenzae cells, which were subjected to electroporation of the voltages indicated. The total number of KanR microcolonies per ml of electroporation mixture is plotted verses the electroporation voltage. Under the

R

conditions used, Kan derivatives of HDG85 were obtained with optimal transduction to KanR at -30 kilovolts/cm.

When electroporation mixtures of H. influenzae and pPX1S75 were plated on selective media, a large number of microcolonies were visible after 24 hours. However, most of these colonies failed to grow further, and did not regrow when subcultured on kanamycin plates. However, after 72 hours, 1-2% of these microcolonies developed into apparently normal H.

influenzae colonies. Cells taken from these colonies regrew under kanamycin selection. No microcolonies 44 were observed and no stable Kan R recombinants were obtained when cells were electroporated with vector DNA, or when cells and pPX1575 were mixed but not electroporated.

EXAMPLE 6 i i 0. 0..

0:6 S00 940~ 20 4 40 2 0 4* 0*4 Transposition in Bordetella Pertussis Transposition of the Kan R determinant contained within the 31 base pair inverted repeat sequence of pPX1575 was demonstrated in B. pertussis strain BP370. Plasmid DNA was introduced into BP370 by electroporation. Transposition events were selected by plating electroporated cells on selective medium containing kanamycin. Kan microcolonies arose with a frequency of greater than per 105 viable cells and were visible on the selection plates within 48 hours post plating. These colonies were grown further and individually tested for regrowth on kanamycin plates and plates containing ampicillin to check for the inheritance of the plasmid vehicle. Of 75 Kan R hemo-

R

lytic colonies tested, none was also Amp

R

By the same token, electroporated cells were plated on medium containing ampicillin to examine the transient inheritance of the plasmid vehicle. The number of KanR colonies arising on selection plates was a 1000 times greater than the number of colonies arising on ampicillin-containing medium. The low frequency of Amp R transformants results from the unstable inheritance of the plasmid vehicle in the recipient cells: approximately 15% of the Amp R clones were simultaneously KanR, suggesting plasmid rearrangements in the recipient cells, as a consequence of expression of the TnJO transposase. These data indicate that high frequency transformation of B. pertussis with DNA unable to replicate stably within the recipient cells 45 but having selectable genetic material contained within 31 base pairs of TnlO inverted repeat DNA results from specific transposition.

It is possible using the cloning vector pPX1575, or derivatives of it suitably modified to contain additional unique restriction enzyme sites and other selectable markers described above, to randomly insert modified pertussis toxin DNA directly into the chromosome of B. pertussis. In an ideal application of this idea, specifically engineered deletion, point, or insertion mutations in the 81 subunit of the pertussis toxin operon, designed to genetically reduce to absolute minimI the toxic activity of pertussis toxin, yet retaining ability to assemble into holotoxin, can be cloned along with its native promoter into appropriate cloning sites of the transposition vector. By electroporating such DNA into host B. pertussis essentially deleted of all host toxin operon sequences and se-

S.

lecting for the co-inherited marker, one or more random 20 insertions of the modified operon can be obtained.

*5 Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experi- :25 mentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

0** 6 46

Claims (17)

1. A DNA construct for introducing a DNA sequence into the constituent DNA of a prokaryotic cell, the construct comprising a gene encoding a transposase protein linked in cis to a transposable cassette, the cassette comprising a pair of transposase recognition sites flanking both a selectable marker gene and a cloning site for insertion of the DNA sequence, but the cassette not having transposition recognition sites that flank both the selectable marker gene and the gene encoding the transposase protein, such that the selectable marker gene and the gene encoding the transposase protein do not both transpose in a single transposition event. ie

2. A DNA construct of Claim 1, wherein the transposable cassette further comprises a selectable marker and the DNA sequence, both the selectable marker and the DNA sequence being flanked by the transposase recognition sites,

3. A DNA construct of Claim 1 or 2, wherein the DNA sequence is an expressible gene from a source selected from the group consisting of bacterial, viral, 1 parasite, fungal and mammalian sources,

4. A DNA construct of any one of Claims 1-3, wherein the pair of transposase Srecognition sites are identical or substantially homologous and functionally equivalent to the transposase recognition sequences of a prokaryotic transposon,

5. A DNA construct of any one of Claims 1-4, wherein the prokaryotic cell is a bacterium and the DNA sequence encodes an antigen capable of stimulating an immune response, o* o S (6 iWRjIEI'/o1WlO0303 TCW

6. A DNA construct of Claim 5, wherein the bacterium is an attenuated enteroinvasive bacterium, se- lected from the group consisting of Escnerichia coli, Yersinia enterocolitica, Shigella flexneri, S. dysenteriae, Campylobacterium jejuni, Vibrio cholerae, Bacille Calmette-Guarin, avirulent mutants of Mycobacterium bovis, Salmonella typhi, Salmonella dublin, Salmonella typhimurium, Salmonella gallinarium, Salmonella paratyphi and Salmonella cholerae suis.

7. An episome for introducing DNA into the constitu- ent DNA of a prokaryotic cell, the episome com- prising: a) a gene encoding a transposase protein; b) a transposable cassette linked in cis to r. the gene encoding the transposase protein, 0G q .j the transposable cassette comprising a pair of inverted repeats flanking a multiple cloning site and a selectable marker, but not flanking the gene encoding the transposase protein; and c) a replicon having an origin of replication which is substantially homologous and functionally equivalent to a prokaryotic origin of replication. .S

8. A bacteriophage derivative for introducing DNA into the constituelnt DNA of a prokaryotic cell, the bacteriophage derl~ative comprising: a) a gene encoding a transposase protein; b) a transposable cassette linked in cis to the gene encoding the transposase protein, the transposable cassette comprising a pair of inverted repeats flanking a multiple cloning site and a 48 49 selectable marker, but not flanking the gene encoding the traisposase protein; and c) n origin of replication which is substantially homologous and functionally equivalent to a bacteriophage origin of replication, 6

9. A live vaccine comprising an attenuated bacterium having incorporated in its constituent DNA a transposable cassette, the cassette comprising a pair of transposase recognition sites flanking both a selectable marker gene and an expressible gene encoding an antigen of interest, but the cassette not having transposition recognition sites that flank both thoe selectable marker gene and the gene encoding the transposase protein, such that the selectable marker gene and the gene encoding the transposase protein do not both transpose in a single transposition event.

A live vaccine of Claim 9, for administration to humans wherein the bacterium is selected from the group consisting of Escherichia colt, Yersinia enterocolitica, Shigella flexneri, Shigella dysenteriae, Campylobacterium jejuni, Vibrio cholerae, Bacille o: 15 Calmette-Guerin and avirulent mutants of Mycobacterium bovis, Salmonella typhi, i Salmonella ablin, Salmonella typhimurium, Salmonella gallinarium, Salmonella paratyphi and Sahnonella cholerae suis,

11, A method for introducing a DNA sequence into the constituent DNA of a prokaryotic cell comprising the steps of, a) introducing a DNA construct into the prokaryotic cell under conditions appropriate for transposition, the DNA construct comprising a gene encoding a transposase protein linked in cis to a transposable cassette, the cassette having a pair of transposase recognition sites flanking both a selectable marker gene and a cloning site for insertion of the DNA sequence, but the cassette not 25 having transposition recognition sites that flank both the selectable marker gene and the gene encoding the transpoiase protein, suh that the selectable 1 marker gene and the gene encoding the transposase protein do not both transpose in a single transposition event; and b) identifying recipient cells having the DNA sequence inserted into the constituent DNA, G0 WPUSEn'tIi0VV0303 TCW

12. A method for introducing a DNA sequence into the constituent DNA of a prokaryotic cell at a pre- determined genetic locus, the prokaryotic cell containing a resident transpason at the pre- detirmined genetic locus, the method a rmprising: a) intrcducing a DNA construct into the pro- karyotic cell, the DNA construct comprising: i) a transposable genetic cassette having a pair of transposase recognition sites flanking a selectable marker and the DNA sequence; ii) a gene encoding a trarsposase protein linked in cis to the transposase cas- sette, the encoder, protein recognizing both the vector born transposase recog- nition sites, and the transposase recog- nition sites of the resideint transposon; and b) identifying prokaryotic cells having the DNA sequence inserted into the constituent DNA of the prokaryotic cell at the predetermined genetic locus. e** S. S 50

13. A DNA construct for introducing a DNA sequence into the constituent DNA of a prokaryotic cell substantially as hereinbefore described with reference to any one of the Examples.

14. An episome for introducing DNA into the constituent DNA of a prokaryotic cell substantially as hereinbefore described with reference to any one of the Examples.

A bacteriophage derivative for introducing DNA into the constituent DNA of a prokaryotic cell substantially as hereinbefore described with reference to any one of the Examples.

16. A live vaccine comprising an attenuated bacterium having incorporated in its constituent DNA a transposablo cassette containing a gene encoding an antigen of interest substantially as hereinbefore described with reference to any one of the Examples,

17. A method for introducing a DNA sequence into the constituent DNA of a prokaryotic cell substantally as hereinbefore described with reference to any one of the Examples. DA ED this SIXTEENTH day of SEPTEMBER 1991 American Cyanamid Company QSV 0* S" Patent Attorneys for the Applicant SPRUSON FEPGUSON O 1 S b _eah:410D 51 INSERTION OF DNA BY MODIFIED TRANSPOSONS Abstract of the Disclosure DNA constructs for the introduction of a DNA sequence into the constituent DNA of a prokaryote, and methods of use. The DNA construct includes an expressible gene encoding a transposase protein, linked in cis to a transposable cassette. The transposable cassette includes a pair of transposase recognition sequences flanking the DNA sequence. The gene encoding the transposase protein is not flanked by the transposase recognition sequences. the invention also provides episomes and bacteriophage derivatives for introducing DNA into the constituent DNA of a prokaryote and live vaccines. *S4* a 4 w .4O eah:410D